| pubmed-article:10782866 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:10782866 | lifeskim:mentions | umls-concept:C0052329 | lld:lifeskim |
| pubmed-article:10782866 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10782866 | pubmed:dateCreated | 2000-5-9 | lld:pubmed |
| pubmed-article:10782866 | pubmed:abstractText | Interleukin-2 (IL-2) and sodium butyrate allow rats to be cured of peritoneal carcinomatosis from colon cancer. We performed a phase I trial of IL-2 and high-dose arginine butyrate (ArgB) in patients with advanced metastatic colorectal cancer. | lld:pubmed |
| pubmed-article:10782866 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10782866 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10782866 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10782866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10782866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10782866 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10782866 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10782866 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:10782866 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:GiacaloneFF | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:MeflahKK | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:DouillardJ... | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:ThomarePP | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:VavasseurFF | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:BennounaJJ | lld:pubmed |
| pubmed-article:10782866 | pubmed:author | pubmed-author:Deporte-FetyR... | lld:pubmed |
| pubmed-article:10782866 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10782866 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:10782866 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10782866 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10782866 | pubmed:pagination | 56-61 | lld:pubmed |
| pubmed-article:10782866 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:meshHeading | pubmed-meshheading:10782866... | lld:pubmed |
| pubmed-article:10782866 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10782866 | pubmed:articleTitle | Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer. | lld:pubmed |
| pubmed-article:10782866 | pubmed:affiliation | Centre René Gauducheau, CRLCC Nantes-Atlantique, Saint-Herblain, France. s-scientifique@nantes.fnclcc.fr | lld:pubmed |
| pubmed-article:10782866 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10782866 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10782866 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10782866 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
